

OTHER MEDICATION ASSISTED TREATMENTS REFERENCES

1. ASAM. [The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use](#). June 2015.
2. SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
3. SAMHSA. [Methadone](#). *SAMHSA.gov*. 2015.
4. Office of National Drug Control Policy. [Medication-Assisted Treatment for Opioid Addiction](#). 2012.
5. Martin J. *Personal Communication Re: Number of Patients Maintained on Buprenorphine*. 2011.
6. Maxwell JC, McCance-Katz EF. [Indicators of buprenorphine and methadone use and abuse: what do we know?](#). *Am J Addict*. 2010;19(1):73-88.
7. Drug Enforcement Administration (DEA). [Buprenorphine](#). 2013.
8. ASAM. [Summary of the Comprehensive Addiction and Recovery Act](#). 2016.
9. Mattick RP, Breen C, Kimber J. [Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence](#). *Cochrane Libr*. 2014.
10. Borg L, Kreek MJ. [The pharmacology of opioids](#). In: *In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine*. Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
11. Lee JD, Friedmann PD, Kinlock TW, et al. [Extended-release naltrexone to prevent opioid relapse in criminal justice offenders](#). *N Engl J Med*. 2016;374:1232-1242.
12. Volkow N. [NIDA-supported science leads to first FDA-approved medication for opioid withdrawal](#). *NIDA*. 2018.
13. PCSS. [Vivitrol: How important is this piece of the treatment puzzle?](#). 2015.
14. PCSS. [XR-Naltrexone: A step-by-step guide](#). 2017.
15. Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). [Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health](#). Washington (DC): US Department of Health and Human Services; 2016.
16. SAMHSA. [Decisions in Recovery. Treatment for Opioid Use Disorder](#). 2017.